Published in Proc Natl Acad Sci U S A on May 19, 2014
ClassTR: Classifying Within-Host Heterogeneity Based on Tandem Repeats with Application to Mycobacterium tuberculosis Infections. PLoS Comput Biol (2016) 1.43
Public health evolutionary biology of antimicrobial resistance: priorities for intervention. Evol Appl (2014) 0.97
Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance? PLoS Comput Biol (2016) 0.89
Evolutionary rescue: linking theory for conservation and medicine. Evol Appl (2014) 0.89
Is selection relevant in the evolutionary emergence of drug resistance? Trends Microbiol (2015) 0.87
Persistence: a copacetic and parsimonious hypothesis for the existence of non-inherited resistance to antibiotics. Curr Opin Microbiol (2014) 0.85
Antibiotic resistance: a primer and call to action. Health Commun (2014) 0.84
A multi-scale approach to designing therapeutics for tuberculosis. Integr Biol (Camb) (2015) 0.82
Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients. Can J Hosp Pharm (2015) 0.81
How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. Elife (2015) 0.79
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. PLoS Biol (2017) 0.79
Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive Treatment. PLoS Comput Biol (2016) 0.78
A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future. Curr Opin Microbiol (2014) 0.78
The Immune Response against Acinetobacter baumannii, an Emerging Pathogen in Nosocomial Infections. Front Immunol (2017) 0.78
Tackling Drug Resistant Infection Outbreaks of Global Pandemic Escherichia coli ST131 Using Evolutionary and Epidemiological Genomics. Microorganisms (2015) 0.75
Diverse drug-resistant subpopulations of Mycobacterium tuberculosis are sustained in continuous culture. J R Soc Interface (2016) 0.75
Profile of Bruce Levin. Proc Natl Acad Sci U S A (2014) 0.75
Fosfomycin enhances phagocyte-mediated killing of Staphylococcus aureus by extracellular traps and reactive oxygen species. Sci Rep (2016) 0.75
Limitations of MIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species. Sci Rep (2016) 0.75
Mathematical Models for Immunology: Current State of the Art and Future Research Directions. Bull Math Biol (2016) 0.75
Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. World J Nephrol (2015) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol (2001) 9.23
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov (2003) 5.48
Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother (1987) 5.17
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics (2000) 4.98
Early programming of T cell populations responding to bacterial infection. J Immunol (2000) 4.57
Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A (1998) 4.28
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother (2003) 4.08
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet (2004) 3.92
Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA (1998) 3.71
Reducing antibiotic resistance. Nature (1996) 3.57
Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A (1997) 3.48
Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A (2004) 3.46
Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet (2011) 3.44
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 2.95
Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol (2001) 2.94
A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis (2007) 2.93
The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother (1997) 2.84
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis (2003) 2.63
The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A (2011) 2.25
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 2.24
Functional relationship between bacterial cell density and the efficacy of antibiotics. J Antimicrob Chemother (2009) 2.24
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2001) 2.23
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest (2002) 2.22
Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog (2009) 2.21
Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother (2005) 2.20
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis (2011) 2.11
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis (2005) 2.10
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother (1995) 2.09
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 2.06
Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother (2000) 2.00
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother (2006) 1.97
Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother (2004) 1.93
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother (2007) 1.93
In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.92
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother (2010) 1.89
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother (1996) 1.88
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.81
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Antibiotic resistance--what's dosing got to do with it? Crit Care Med (2008) 1.67
Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis (1998) 1.66
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol (2007) 1.64
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis (2011) 1.52
Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4(+) T cells. J Immunol (2002) 1.50
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother (2010) 1.44
Kinetics of antimicrobial action. Rev Infect Dis (1981) 1.41
Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother (2006) 1.39
A model of antibiotic-resistant bacterial epidemics in hospitals. Proc Natl Acad Sci U S A (2005) 1.29
Address in Pathology, ON CHEMIOTHERAPY: Delivered before the Seventeenth International Congress of Medicine. Br Med J (1913) 1.28
Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites. Evolution (2010) 1.27
Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. J Theor Biol (2007) 1.24
Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet (2013) 1.23
Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis (2007) 1.21
Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis (2004) 1.19
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.19
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2003) 1.17
Kinetics and mechanisms of action of antibiotics on microorganisms. V. Chloramphenicol and tetracycline affected Escherichia coli generation rates. J Pharm Sci (1966) 1.15
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat (2011) 1.14
The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci (2003) 1.13
The impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteria. PLoS One (2008) 1.12
High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins. Antimicrob Agents Chemother (1996) 1.11
Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog (2012) 1.06
Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother (2000) 1.05
"One-size-fits-all"? Optimizing treatment duration for bacterial infections. PLoS One (2012) 1.05
Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis (1998) 1.01
Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrob Agents Chemother (2010) 1.00
Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol (2008) 0.99
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother (2002) 0.98
Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. Antimicrob Agents Chemother (1998) 0.96
Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother (1994) 0.94
Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother (2003) 0.94
The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations. PLoS Pathog (2013) 0.93
The problems of antibiotic overuse. Scand J Prim Health Care (2010) 0.93
The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother (2001) 0.92
On the control of acute rodent malaria infections by innate immunity. PLoS One (2010) 0.91
Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother (2005) 0.90
Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother (2003) 0.90
Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros (2008) 0.87
Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother (2002) 0.87
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother (2007) 0.80
Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin Infect Dis (2003) 0.79